Amyris, Inc.

What they make

1 input Amyris, Inc. supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Substitution2024

  Squalene leads a startling double life: it's a prized moisturizer in skincare (sold as squalane, in countless face creams and serums) and, separately, a critical base for vaccine adjuvants — the immune-boosting component in pandemic-flu vaccine adjuvants like MF59. And for most of history it came from one grim source: shark liver oil, with millions of deep-sea sharks killed to supply it. Amyris attacked that with synthetic biology, engineering yeast to ferment sugarcane sugar into squalane, brewing the molecule without any sharks at all. So a single synbio company makes a sustainable, shark-free version of an ingredient that sits simultaneously in your bathroom cabinet and in vaccines — decoupling both the beauty and the pandemic-preparedness supply chains from a marine-animal feedstock. It's one of the cleaner dual-use stories in this radar: the very same molecule moisturizes skin and helps a vaccine work, and switching its origin from sharks to microbes quietly serves conservation, cosmetics and public health at once. [verify: Amyris yeast-fermented sugarcane squalane, shark-free, MF59 dual-use confirmed]

  Amyris, Inc. ↗

• Incident2023

  Amyris is a cautionary tale about the gap between a brilliant technology and a viable business. It was a flagship of synthetic biology — beyond squalane, its engineered yeast produced a low-cost precursor for the antimalarial drug artemisinin, plus fragrance molecules, sweeteners and biofuel components, proving you really could "brew" complex, valuable chemicals with microbes instead of extracting them from plants, animals or petroleum. The science largely worked. But the company overextended, especially in pouring money into building its own consumer beauty brands, and in 2023 it filed for Chapter 11 bankruptcy, its assets later sold off. So the firm that helped prove microbial manufacturing could replace shark livers and rainforest extraction collapsed financially even as its molecules kept being used. It's a sharp reminder that a technically successful chokepoint-buster — a sustainable substitute for a constrained natural feedstock — does not guarantee a durable company, and that scaling and commercializing synthetic biology has repeatedly proven far harder than the lab breakthroughs that make headlines.

  Amyris, Inc. ↗

• Concentration2024

  The squalene-for-vaccines question is a real pandemic-preparedness concern, and it explains why companies like Amyris matter beyond cosmetics. Adjuvanted vaccines can stretch limited antigen supply — letting a smaller dose protect more people — which makes squalene-based adjuvants strategically important during a pandemic. But sourcing that squalene from sharks is both ecologically destructive and supply-constrained (you can't quickly scale shark fishing for a pandemic), so health authorities and manufacturers increasingly look to plant-derived (e.g. olive/amaranth) and fermentation-derived squalene as secure, scalable, ethical alternatives. Amyris's sugarcane-fermented squalane is one such option, alongside plant-extraction specialists. So an ingredient most people know only as a skincare moisturizer is quietly part of biosecurity planning: ensuring a non-shark, rapidly scalable squalene supply is part of how the world prepares to vaccinate billions in the next pandemic — another case where a seemingly cosmetic input turns out to sit in a critical-medicine supply chain.

  Amyris, Inc. ↗